Contents

Chapter 1 General Introduction

Section I Immunogenicity

Chapter 2

2.1 Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation. 

2.2 Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. 

Chapter 3

3.1 Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation. 

3.2 Adalimumab in juvenile rheumatoid arthritis. Comment on the article by Lovell and colleagues. 

Chapter 4

Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. 

Section II Biomarkers of disease activity and cardiovascular risk

Chapter 5

5.1 Erythrocyte sedimentation rate, C-reactive protein level and serum amyloid A protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis. 

5.2 C-reactive protein polymorphisms and haplotypes influence serum C-reactive protein levels independent of disease activity in ankylosing spondylitis. 
Submitted
Chapter 6


Chapter 7

Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis. *Arthritis and Rheumatism* 2009;60(5):1324-1330.

Section III

Extraspinal manifestations


Chapter 10 General Discussion and Summary

Chapter 11 Nederlandse Samenvatting

Appendix Questionnaires and BASMI Abbreviations List Dankwoord Curriculum Vitae